Navigation Links
If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
Date:2/11/2009

Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if Genentech/Roche/Chugai's Herceptin is approved in combination with emerging therapies, it will be in a position to retain patient share from GlaxoSmithKline's Tykerb/Tyverb for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This is particularly true in the second- and subsequent HER2-positive treatment lines which are currently its most vulnerable market segments.

The new report entitled HER2-Positive Breast Cancer: Oncologists Are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting also finds that Genentech/Roche/Chugai's pertuzumab in combination with Herceptin and Sanofi Aventis' Taxotere will become Decision Resources' proprietary clinical gold standard regimen for HER2-positive breast cancer by 2017. This will occur following its approval for the indication in combination with Herceptin and Taxotere in 2013.

"Based on surveys and interviews we conducted with U.S. and European oncologists, as well as comparative drug analysis using our proprietary drug comparator model, we concluded that pertuzumab will have competitive advantages in efficacy when used in combination with Herceptin and Taxotere versus using Herceptin and Taxotere alone," stated Niamh Murphy, Ph.D., analyst at Decision Resources.

About the Report

HER2-Positive Breast Cancer: Oncologists are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
2. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
3. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
4. Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
5. A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009
6. CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
7. Alliance for Pediatric Quality Supports New ANSI-Approved Standard for Child Health Passed by HL7
8. New Roche Dual Target HIV-1 Test Approved for Use in European Union
9. The First Treatment Specifically Approved for Huntingtons Disease Patients is Now Available in the United States
10. Bayer Marketing Two Unapproved Aspirin Products: FDA
11. Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... The Cancer Solution: Taking Charge of Your Life with ... book the Booksandauthor reviewer ever read about the ... what should be one of the most important books anyone ... in action and this book has both. , Cancer is ... and unfortunately many persons know little about it. Dr. Westman ...
(Date:5/28/2015)... Aurora, Colo. (PRWEB) May 28, 2015 The ... features two very different people who share a need to ... firefighter from outside of Omaha, NE, struggling to deal with ... a former college basketball player from Kansas City, MO, who ... , Josh and Kelli’s amazing transformations will be featured in ...
(Date:5/27/2015)... Throughout the past few months, Push to Walk ... validity and reliability of the Shaw Gait Assessment in comparison ... Professor in the Department of Physical Therapy at Seton Hall ... Shaw Gait Assessment is a free online tool, where the ... is considered the gold standard in providing information about how ...
(Date:5/27/2015)... (PRWEB) May 28, 2015 Thermage was the ... Precision Aesthetics was founded in 2007 coinciding with the release ... Thermage. In fact, Precision Aesthetics was the first practice ... The new platform produced results that had never been ... its inception, Thermage is still considered by many as the ...
(Date:5/27/2015)... Down is a reputable source of 2015 NHL Western Conference ... middle of their series against the Anaheim Ducks with the Ducks ... can win tonight at home, this will tie up the series ... Honda Center in Anaheim. , During the regular season, the ... they won the Pacific Division by 8 points ahead of the ...
Breaking Medicine News(10 mins):Health News:Booksandauthor Cites The Cancer Solution as One of the Most Important Books to Read 2Health News:“Extreme Weight Loss”: Josh and Kelli’s Journeys Begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:“Extreme Weight Loss”: Josh and Kelli’s Journeys Begin at the University of Colorado Anschutz Health and Wellness Center 3Health News:Push to Walk Partners with Seton Hall University for Study 2Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2
... for the second year in a row, according to U.S.News & World ... ... Health Plan of Michigan,has been recognized as one of the Top 15 Medicaid ... Health Plans rankings. HPM was ranked 14th nationally and was also the,second highest-ranked ...
... Ltd. a global,developer, manufacturer and marketer of laser, ... applications,announced today that it will introduce four new ... the American Academy of Ophthalmology,(AAO) Annual Meeting in ... Chief Executive Officer stated:,"Lumenis is proud to be ...
... MENTOR, Ohio, Nov. 6 STERIS Corporation,(NYSE: STE ... 11, 2008,due to lower attendance than anticipated. The Company ... its shareholder base can,attend is the most prudent action ... causes to shareholders and sell-side analysts., About STERIS, ...
... 6 Nektar,Therapeutics (Nasdaq: NKTR ) today announced ... outstanding convertible debt for approximately 48,cents on the dollar, ... also reported its financial results for the third quarter ... Nektar is now largely complete," said Nektar,President and CEO ...
... bringing total to 79, CDC says , , THURSDAY, Nov. 6 ... with salmonella traced to dry dog food have been identified, ... in 2006, marks the first time that dry dog food ... in people. , As of Oct. 31, 79 cases of ...
... Trust for America,s,Health (TFAH) supports the Government Accountability ... to focus on food safety,and preparing for large-scale health ... the country. The GAO released a list of top ... "The GAO recognized that the public health concerns of ...
Cached Medicine News:Health News:Health Plan of Michigan Ranked Among Nation's Best Medicaid Health Plans in 2008 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 3Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 4Health News:STERIS Corporation Postpones Analyst Day 2Health News:STERIS Corporation Postpones Analyst Day 3Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 2Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 3Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 4Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 5Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 6Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 7Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 8Health News:Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results 9Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 2Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 3
(Date:5/27/2015)... MADISON, Wis. , May 27, 2015   Madison ... specialty clinic in Madison and the ... a commitment to results, Madison Laser Tattoo Removal is dedicated ... in southern Wisconsin . "I ... to their unwanted ink and return their skin to its ...
(Date:5/27/2015)... OpportunityAnalyzer: Cushing,s Syndrome - Opportunity Analysis ... estimates that the 2013 sales for the Cushing,s ... the 6MM covered in this report. Pharmaceutical and ... and financial resources in the CS field, have ... strategies. One notable example is the fact that ...
(Date:5/27/2015)... -- The prevalence of cardiovascular disease in ... and changes in consumption concept, dietary habit, way of ... year, thereby promoting the development of domestic percutaneous coronary ... totaled 454,505 in 2013, up 16.9% from ... there was worth RMB20.12 billion. At present, half ...
Breaking Medicine Technology:Madison Laser Tattoo Removal Brings Superior Laser Tattoo Removal Services To Madison, WI With Astanza Duality 2OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 2OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3
... AMD patients, LOUISVILLE, Ky., Sept. 29 ... for the treatment,of age-related macular degeneration (AMD) announced ... shown early positive safety,results in its Phase I ... the complement activation cascade that could otherwise lead ...
... Foundation to improve healthcare,system in the Democratic Republic ... The Clinton Global,Initiative recognized BD (Becton, Dickinson ... medical technology company, for its commitment to the,Dikembe ... and,healthcare worker safety at the Biamba Marie Mutombo ...
Cached Medicine Technology:Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 3
Inquire...
Supercassette quick release holder for the 8000 Series sliding microtome to allow for the use of wax supercassettes, 75x52x19 mm....
... 5040 microtome is of rotary retracting, self-lubricating design ... cutting arm. Its robust construction makes it accurate ... hinges means that all lateral motion is controlled ... be experienced in other, lesser designs which can ...
Spare fuse set...
Medicine Products: